DBV Technologies: Two Regulatory Submissions Planned in 2026 for Viaskin Peanut Patch
DBV Technologies unveils its regulatory submission schedule for its flagship pediatric allergy treatment. The French biotech plans two biologics license applications (BLA) this year, respectively for children aged 4 to 7 years and toddlers aged 1 to 3 years, as well as the launch of a new Phase 2 study in infants aged 6 to 12 months.
DBV Technologies sets a brisk pace for its flagship candidate, the VIASKIN Peanut patch. The company plans to file its first biologics license application in the first half of 2026 for children aged 4 to 7 years, followed by a second submission in the second half for the 1 to 3-year-old age group. This dual request covers an extension of the pediatric population allergic to peanuts, potentially broadening the accessible patient base. Daniel Tassé, CEO, emphasized an approach marked by 'extreme precision and determination' in product development.
A Groundbreaking Study Planned for Very Young Children
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Beyond regulatory filings, DBV announces the initiation of the THRIVE trial, a Phase 2 study aimed at infants aged 6 to 12 months. This trial will assess the efficacy and safety of the VIASKIN Peanut patch to enable peanut consumption after at least three years of treatment. The study was announced last year at the American College of Asthma, Allergy, and Immunology congress. Its launch represents an extension of the treatment strategy to younger patients, thus covering the entire spectrum of pediatric ages allergic to peanuts.
Execution Challenges and Regulatory Visibility
These three milestones (two BLAs and a new study) position DBV Technologies at a pivotal phase of its development in 2026. The concentration of these major events in a single year will be decisive for the future commercial trajectory of the group.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1M€dedollars
Net income: -47,6M€dedollars
Free cash flow: -49M€dedollars
Guidance from the release
Toute l'équipe de DBV démontre une focalisation et une rigueur exceptionnelles alors que nous abordons des étapes décisives au cours des prochains mois.
Risks mentioned
Augmentation significative des dépenses de R&D.
Perte nette en hausse à 47,6 millions de dollars.
Opportunities identified
Dépôt de la demande de licence biologique prévu pour 2026.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
